Trials / Completed
CompletedNCT05438173
Bioavailability of EPA/DHA in of Ruby-O and Krill Oil
A Randomized, Double-Blind, Crossover, Kinetic Study to Assess the Relative Bioavailability of Omega-3 Fatty Acids in Two Supplement Products in Healthy Adult Men and Women
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Midwest Center for Metabolic and Cardiovascular Research · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to assess the relative bioavailability of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in two supplement products in healthy adult men and women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | EPA + DHA Ruby-O | Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule |
| DIETARY_SUPPLEMENT | EPA + DHA Krill Oil | Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule |
Timeline
- Start date
- 2022-07-11
- Primary completion
- 2022-09-18
- Completion
- 2022-09-18
- First posted
- 2022-06-29
- Last updated
- 2022-12-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05438173. Inclusion in this directory is not an endorsement.